Aquestive Therapeutics, Inc. Revenues
Aquestive Therapeutics, Inc. (AQST) reported Revenues of $16.82 million for the 3-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2019-03-14
- Aquestive Therapeutics, Inc. revenues for the quarter ending 2018-12-31 was $16.82M, a 37.97% increase year-over-year.
- Aquestive Therapeutics, Inc. revenues for the quarter ending 2018-09-30 was $13.27M, a 51.13% decline year-over-year.
- Aquestive Therapeutics, Inc. revenues for the quarter ending 2018-06-30 was $13.93M, a 25.00% increase year-over-year.
- Aquestive Therapeutics, Inc. revenues for the quarter ending 2018-03-31 was $23.41M, a 42.44% increase year-over-year.
- Aquestive Therapeutics, Inc. revenues for fiscal 2018 was $67.43M, a 0.77% increase from fiscal 2017.
- Aquestive Therapeutics, Inc. revenues for fiscal 2017 was $66.92M.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-12-31 | $16.82M 10-K · filed 2019-03-14 | $30.09M derived: sum of 2 quarters · filed 2019-03-14 | $44.02M derived: sum of 3 quarters · filed 2019-03-14 | $67.43M 10-K · filed 2019-03-14 |
| 2018-09-30 | $13.27M 10-K · filed 2019-03-14 | $27.20M derived: sum of 2 quarters · filed 2019-03-14 | $50.61M 10-Q · filed 2018-11-06 | $62.80M derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | $13.93M 10-K · filed 2019-03-14 | $37.34M 10-Q · filed 2018-09-04 | $49.53M derived: sum of 3 quarters · filed 2019-03-14 | $76.68M derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | $23.41M 10-K · filed 2019-03-14 | $35.60M derived: sum of 2 quarters · filed 2019-03-14 | $62.75M derived: sum of 3 quarters · filed 2019-03-14 | $73.89M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | $12.19M 10-K · filed 2019-03-14 | $39.34M derived: sum of 2 quarters · filed 2019-03-14 | $50.48M derived: sum of 3 quarters · filed 2019-03-14 | $66.92M 10-K · filed 2019-03-14 |
| 2017-09-30 | $27.15M 10-K · filed 2019-03-14 | $38.29M derived: sum of 2 quarters · filed 2019-03-14 | $54.72M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $11.14M 10-K · filed 2019-03-14 | $27.58M 10-Q · filed 2018-09-04 | ||
| 2017-03-31 | $16.44M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |